^
Association details:
| Biomarker: | EGFR positive |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | MRG003 (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial
Published date:
07/01/2022
Excerpt:
The findings of this nonrandomized clinical trial suggest that MRG003 showed a manageable safety profile and promising antitumor activity in patients with EGFR-positive NPC and SCCHN.
DOI:
10.1001/jamaoncol.2022.0503
